Market Place
Sourcing Support
Takeda Receives EU Approval for FRUZAQLA
22 Jun 2024 //
PRESS RELEASE
Trifluridine/Tipiracil Plus Bevacizumab Provides Potential 1st-Line Alternative
30 Aug 2023 //
ONCLIVE
Natco`s Generic Tipiracil HCL, Trifluridine Receives Approval in the U.S.
13 Jun 2023 //
FDA
XBiotech Announces First Patient Enrolled French(INCA) Ph I/II/III Natrunix™
13 Oct 2022 //
GLOBENEWSWIRE
XBiotech Announces ANSM Approval, INSA funding for PII/III Study for Natrunix
28 Apr 2022 //
GLOBENEWSWIRE
NATCO Pharma launches Tipanat tablets for advanced colorectal, gastric cancer
23 Nov 2021 //
INDIAINFOLINE
Natco Pharma launches Tipanat tabs for colorectal and gastric cancer
18 Nov 2021 //
PHARMABIZ
LONSURF®trifluridine/tipiracil Receives Marketing Authorization EU for Patient
05 Sep 2019 //
BUSINESSWIRE
FDA Approves Taiho Oncology`s LONSURF® (trifluridine/tipiracil)
25 Feb 2019 //
PR NEWSWIRE
Servier and Taiho Oncology Present Latest LONSURF® (trifluridine/tipiracil) Data
18 Jan 2019 //
BUSINESSWIRE
Taiho Oncology & Servier to Present Data on LONSURF® (trifluridine & tipiracil)
14 Jun 2018 //
PR NEWSWIRE
Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF®
07 Jun 2018 //
PR NEWSWIRE
Taiho Pharma Canada, Inc. announces Health Canada approval of LONSURF®
06 Mar 2018 //
NEWSWIRE
Bayer`s struggling Stivarga moves closer to liver-cancer lifeline
04 Jan 2017 //
FIERCE PHARMA
Servier`s Lonsurf approved in Europe for colorectal cancer
27 Apr 2016 //
PHARMA TIMES
CHMP Issues Opinion for LONSURF for Refractory Metastatic Colorectal Cancer
29 Feb 2016 //
PR NEWSWIRE
Taiho, Servier sign exclusive license agreement to develop and commercialize TAS-102 drug
15 Jun 2015 //
NEWS MEDICAL
Taiho Submits Colorectal Cancer Drug In Europe
03 Mar 2015 //
PHARMATIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.